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Nevertheless, this system is faster than a nurse-based system,
which might be the reason for its better effectiveness. It would have
been interesting to see data on the average time span between
problem detection and relay of information to the treating physi-
cian and between the time when information was received and
execution of changes in patient care. A reduction of this time
span—as in acute coronary care—could be the key to further
reduce mortality rates, particularly with regards to sudden death.
Additional information on the cause of death would have been
important. We hypothesize that in the present study, nurse-led
care as well as telemedicine, compared to usual care, reduced the
occurrence of death due to progressive deterioration of cardiac
failure, but not the rate of sudden death. When developing future
telemedical systems, we need to carefuly evaluate the different
parameters for their contribution in making meaningful therapeu-
tic decisions. Do the researchers have data on which information
was required in making management decisions?
The medical impact of third-generation telemedical systems
will be direct and immediate. Decisions will be based on incoming
data, the patient’s history, current treatment, and direct patient
contact. Such systems are in development (2). The introduction of
these systems will allow development of telemedical systems into
tele-home-care networks that assist physicians and nurses in the
ambulatory treatment of CHF patients. Havranek (3), suggested
that telemedical approaches will be successful when the involved
parties know each other. We agree, and we believe that only a
third-generation telemedical system will be able to achieve this.
*Friedrich Koehler, MD
Stefan D. Anker, MD, PhD
*Charité-Universitätsmedizin Berlin
Department of Cardiology, Campus Mitte
Charitéplatz 1
D-10117 Berlin
Germany
E-mail: friedrich.koehler@charite.de
doi:10.1016/j.jacc.2006.05.033
REFERENCES
1. Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH. Noninvasive
home telemonitoring for patients with heart failure at high risk of
recurrent admission and death: the Trans-European Network–Home-
Care Management System (TEN–HMS) study. J Am Coll Cardiol
2005;45:1654–64.
2. Next Generation Media. Available at: www.nextgenerationmedia.de.
Accessed June 2, 2006.
3. Havranek EP. Improving the outcomes of heart failure care: putting
technology second. J Am Coll Cardiol 2005;45:1665–6.
REPLY
We thank Dr. Chan and colleagues for their compliments about
TEN-HMS (Trans-European Network–Home-Care Management
System) and its primary end point (1). We agree that time-to-first-
event analyses of composite outcomes are difficult to interpret and
may be clinically misleading. Time-to-first event analysis is a
powerful statistical tool, but it does appear that the “servant has
become the master” in the design and analysis of many contem-
porary clinical trials. Patients with serious, symptomatic conditions
have similar goals to most other people; they want to live a long
and happy life. The emphasis on well-being and longevity will vary
depending on the severity of symptoms and the expectations of the
individual. Accordingly, clinical trials should try to capture this
information, and composite outcomes are the preferred health
measure because neither well-being nor longevity alone describes
what most patients want.
Time-to-event analysis is clearly appropriate for mortality but not
for most other outcomes in trials of heart failure; this is because it
ignores all events subsequent to the first and ignores the potential of
many patients to make a good recovery from what may be a minor
incident. The reason for the continued popularity of this test is its
track record, which has had the unfortunate side effect of suppressing
the development of alternatives. There is no doubt that alternatives are
required, but these new and more clinically sensible tools also need to
be subjected to testing and critical analysis in terms of their internal
logic, relevance, and statistical power.
It is clear that the measure of days-alive and out of hospital is not
going to be a robust end point for most clinical trials because of the
skewed distribution and large variation among individuals. Also,
hospitalization is generally being used as a surrogate measure for
well-being, and the validity of this assumption has not been ade-
quately tested. Outcomes such as “Patient-Journey” or QALY (quality
adjusted life-years) are easily measured and describe effects both on
well-being and longevity (2). The distribution of derived values is
more normally distributed than days-alive and out of hospital, and
therefore statistical testing is more straightforward and powerful. Very
simple quality-of-life or symptom-assessment tools should be used as
patients may tire of filling in complex questionnaires repetitively. The
method suggested by Dr. Chan and colleagues and variations on that
theme used by others is certainly an attractive, alternative method for
assessing the effects of therapy (3). However, we believe that this
approach is better suited to medium-sized studies investigating the
mechanism of drug effect. Such studies provide valuable information
that will help decide whether it is worth proceeding to a definitive
outcome study and whether its primary end point should be all-cause
mortality, “Patient-Journey,” or QALY.
We also thank Drs. Koehler and Anker for their comments. We
would have liked to take the credit for being the first study of
telemedicine to show a reduction in mortality, but, in fact, we were
only the second study to do so (4). Also, the DIAL (ranDomised trial
of telephone Intervention in chronic heArt faiLure) study showed a
reduction in hospitalizations for heart failure, although not mortality,
in a very simple telemedicine project (5). The TEN-HMS trial shows
one of the largest absolute differences in mortality for any intervention
in heart failure. Accordingly, there is already more evidence of a
mortality benefit from telemedicine in heart failure than for many
other interventions. It is hoped that the next round of guidelines will
recognize the importance of organization of care, which is greatly
assisted by telemedicine, for patients with heart failure.
Hospitalization makes up just a small fraction of the patient
experience of heart failure. Evolutions and revolutions in care are
likely to increase expenditures on out-of-hospital care dispropor-
tionately. We believe that the importance of hospital care for
patients with heart failure will diminish in the future owing to
improvements in treatment, the delivery of care, and the develop-
ment of hospices for the terminally ill.
Drs. Koehler and Anker rightly point out that telecare is still in
its infancy and is only now approaching the threshold of main-
stream medicine. Much more work is required on integrating
health professionals into this system of care. We are confident that
a telemedicine strategy can offer much greater benefit than we
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could demonstrate in TEN-HMS. We had no learning period to
identify appropriate triggers and responses to the new information
being acquired. The analyses they request are only now being done;
the techniques required are complex to apply. We also agree that
remote telemonitoring by people who have little knowledge of the
patient and who are not in a position to offer practical help if
needed is unlikely to be optimal. Telemedicine that integrates care
at the local and regional level is most likely to meet with success.
*John G. F. Cleland, MD
*Department of Cardiology
University of Hull
Castle Hill Hospital
Castle Road
Kingston-upon-Hull
HU16 5JQ
United Kingdom
E-mail: j.g.cleland@hull.ac.uk
doi:10.1016/j.jacc.2006.05.032
REFERENCES
1. Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH. Noninvasive
home telemonitoring for patients with heart failure at high risk of
recurrent admission and death: the Trans-European Network–Home-
Care Management System (TEN–HMS) study. J Am Coll Cardiol
2005;45:1654–64.
2. Cleland JGF. How to assess new treatments for the management of
heart failure: composite scoring systems to assess the patients’ clinical
journey. Eur J Heart Fail 2002;4:243–7.
3. Abraham WT, Fisher WG, Smith AL, et al., for the MIRACLE Study
Group. Cardiac resynchronization in chronic heart failure. N Engl
J Med 2002;346:1845–53.
4. Goldberg LR, Piette JD, Wals MN, et al., on behalf of the WHARF
Investigators. Randomized trial of a daily electronic home monitoring
system in patients with adavanced heart failure: the Weight Monitoring
in Heart Failure (WHARF) trial. Am Heart J 2003;146:705–12.
5. GESICA Investigators. Randomised trial of telephone intervention in
chronic heart failure: DIAL trial. BMJ 2005;331:425–30.
Pleiotropic Effects of Statins and Early
Benefit in the PROVE IT–TIMI-22 Study
Ray et al. (1) discuss the early and late benefits of 80 mg/day of
atorvastatin in the acute coronary syndrome patients of the
PROVE IT–TIMI-22 (Pravastatin or Atorvastatin Evaluation
and Infection Trial–Thrombolysis In Myocardial Infarction-22),
and they conclude that the early benefit observed in this trial is
likely due to the pleiotropic effects of the statin used.
Conversely, the difference in the triple end-point incidence they
observe after 30 days, as can be seen in Table 1 of their study, is
limited to patients with plasma low density lipoprotein (LDL)
cholesterol levels 125 mg/dl at randomization (hazard ratio
[HR] 0.31; 95% confidence interval [CI] 0.15 to 0.64; p  0.002),
whereas it is completely absent in patients with LDL cholesterol
125 mg/dl at randomization (HR 0.92; 95% CI 0.63 to 1.36; p
 0.7). It is intriguing that a purported nonlipidic effect of a statin
is observed only in patients with elevated LDL cholesterol.
Pleiotropic effects should, conceptually, exert their protective
properties at any lipid level.
Attribution of the early protective action observed in the
PROVE IT–TIMI-22 trial to the pleiotropic effects of the statin
used should be, in our opinion, more cautious. In actuality, a clear
demonstration of the clinical relevance of these effects is still
lacking. A recent meta-regression of published clinical trials
testing different hypolipidemic treatments concludes that choles-
terol reduction is likely to be the major (or unique) determinant of
coronary heart disease and stroke events reduction (2).
Indeed, LDL reduction obtained by a single LDL apheresis
markedly reduces C-reactive protein and ameliorates the endothe-
lial function of coronary arteries (3), suggesting that LDL reduc-
tion, by itself, can rapidly translate into a variety of biochemical or
clinical benefits. Perhaps we should abandon the concept of
“pleiotropic effects of statins” in favor of that of “pleiotropic effects
of cholesterol reduction.”
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REPLY
We thank Drs. Poli and Pujia for their interest in our report (1). They
suggest that the more significant reduction in clinical events observed
among patients with a high low-density lipoprotein cholesterol
(LDL-C) versus those with a low LDL-C at baseline provides
evidence that the early benefits observed at 30 days are related more to
lipids than any potential pleiotropic effects. Acute coronary syndrome
(ACS) patients have a high early recurrence of adverse events after
ACS. The significant early benefits of intensive statin therapy ob-
served by day 30 in the PROVE IT–TIMI-22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction-22) trial seem more striking when compared to
the benefits of intensive LDL-C reduction by ileal bypass in the
POSCH (Program on the Surgical Control of the Hyperlipidemias)
study, which took nearly seven years to translate into clinical benefit
(2). Similarly, in the early statin trials in stable coronary artery disease
(CAD) the benefits of statins were observed after one to two years,
suggesting that in stable patients the benefits of modest reductions in
LDL-C take place over a period of years rather than days. Whereas
we agree that LDL-C reduction itself is associated with reductions in
C-reactive protein (CRP) and endothelial function, we have demon-
strated that, independent of achieved LDL-C and other correlates,
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